Howard Rosen

Alcobra Ltd. engages in the research, development, and market of pharmaceutical productsfor the treatment of central nervous system disorders and cognitive dysfunctions. Its portfolio includes Metadoxine Extended Release to treat Attention Deficit Hyperactivity Disorder and Fragile X Syndrome. The company was founded by Ehud Moshe Gilboa and Dalia Megiddo on February 7, 2008 and is headquartered in Tel Aviv, Israel.

McKinsey & Co., Inc. provides management consulting services. It specializes in design, marketing and sales, analytics, operations, transformation and restructuring, risk, strategy and corporate finance, and sustainability and resource productivity. The company was founded by James O. McKinsey in 1926 and is headquartered in New York, NY.

GenPharm International, Inc. manufactures biopharmaceutical products. The company works towards the application of transgenic animal technology to the development of human antibody products, which are used for therapeutic uses. It was founded in 1988 and is located in San Jose, CA.

Integral, Inc. provides internet consulting and web development services. Its services include virtual private networking, network security, on-side service, troubleshooting and monitoring. The company was founded by Vadim Levy on November 4, 1998 and is headquartered in Montgomery Village, MD.

Part of The National Academies of Science, the National Academy of Engineering operates as a professional membership organization. The company is based in Washington.

Pearl Therapeutics, Inc. develops therapies for the treatment of chronic respiratory diseases. It offers respiratory product development, high quality therapies for COPD, Asthma and treatment and prevention of chronic respiratory diseases and asthma. The company was founded in 2006 by Sarvajna Dwivedi and is headquartered in Redwood City, CA.

Hammerton, Inc. is a company that specializes in designing and crafting American-made lighting fixtures. The private company is based in Salt Lake City, UT. With over 25 years of experience, the company has become a leader in custom lighting design, engineering, and manufacturing. The company's team of 150 employees has created lighting fixtures for various establishments, including hotels, restaurants, luxury resorts, corporate headquarters, private clubs, and residences worldwide.

Entrega, Inc. develops oral drug delivery technologies. The firm’s platform enables novel applications in a variety of fields, such as disease management and tracking in the burgeoning mobile health arena. Its proprietary technology seeks to solve the oral delivery problem with an engineering solution that protects the payload and delivers biological molecules, drug substances and nanoparticles. The company was founded by Samir Mitragotri in 2010 and is headquartered in Boston, MA.

The Mit Club of Northern California is a regional alumni club of Massachusetts Institute of Technology. The non-profit company is based in Northern California. The club is run by volunteer MIT alums and organizes around one hundred events every year, serving over 15,000 alumni. The club promotes design and innovation through an interdisciplinary approach, with emphasis on collaborative exploration and problem solving.

twoXAR, Inc. provides drug discovery services. Its DUMA platform rapidly evaluates massive public and proprietary datasets to identify and rank probability drug-disease matches. The company was founded by Andrew A. Radin and Andrew M. Radin in 2014 and is headquartered in Palo Alto, CA.

Metera Pharmaceuticals, Inc. manufactures pharmaceutical products. The company is headquartered in Newton, MA.

Hopewell Therapeutics, Inc. is a company that is focused on discovering, synthesizing, and developing tissue-targeted lipid nanoparticles (TTLNPs) to bring genomic medicines to patients. The company is based in Woburn, MA and was founded in 2018 by Qiaobing Xu. Hopewell is pursuing opportunities to redefine the non-viral delivery space for novel genomic medicines by designing systemically administered LNPs to specifically target extrahepatic tissues and cells throughout the body. The company has built a robust intellectual property portfolio with an expansive library of ionizable lipids and has established partnerships with several industry-leading companies. Hopewell is developing its own internal pipeline, initially targeting diseases of the lung, while concurrently exploring the potential of its TTLNP platform for patients with unmet needs in oncology, infectious diseases, rare genetic diseases, and neurological disorders. Louis Brenner has been the CEO of the company since 2022.

Firecyte Therapeutics, Inc. is an emerging biotechnology company based in Cambridge, MA that is focused on developing novel treatment strategies for progressive neurodegenerative diseases of the eye. The company's research is centered around the role of microglia and neuroinflammation in these diseases. The team is led by Jonathan Levenson, the Chief Scientific Officer, who has over 16 years of experience in neuropsychiatry, neurodegeneration, and neuroinflammation. The company was founded by Dong Feng Chen and William E. Yelle, who has been the CEO since incorporation.